Susceptibility of streptomycin-resistant Mycobacterium tuberculosis strains to amikacin.
A total of 585 Mycobacterium tuberculosis strains isolated during a three-year period in Sweden were tested for in vitro susceptibility to amikacin in comparison with streptomycin. Resistance to streptomycin was seen in 27 of the isolates (4.6%). These isolates had been obtained from 22 patients, a majority of which were non-European immigrants. All but one of the streptomycin-resistant isolates were susceptible to amikacin. None of 263 streptomycin-susceptible isolates tested was resistant to amikacin. Amikacin appears to be an alternative to streptomycin in the treatment of patients with streptomycin-resistant Mycobacterium tuberculosis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000494:pharmacology*; D002675:Child, Preschool; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D013307:Streptomycin / Q000494:pharmacology; D013548:Sweden
D000583:Amikacin; D013307:Streptomycin